Qube Research & Technologies Ltd - CTI BIOPHARMA CORP ownership

CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 133 filers reported holding CTI BIOPHARMA CORP in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.

Quarter-by-quarter ownership
Qube Research & Technologies Ltd ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q1 2023$253,928
-66.5%
60,459
-62.8%
0.00%
-83.3%
Q1 2022$758,000
+715.1%
162,309
+331.4%
0.01%
+500.0%
Q4 2021$93,000
+27.4%
37,626
+52.4%
0.00%0.0%
Q3 2021$73,000
-39.7%
24,688
-40.6%
0.00%
-50.0%
Q1 2021$121,000
-78.0%
41,593
-75.6%
0.00%
-75.0%
Q4 2020$549,000170,5830.01%
Other shareholders
CTI BIOPHARMA CORP shareholders Q1 2023
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 4,068,191$4,719,0009.14%
CAXTON CORP 619,460$719,0000.76%
BVF INC/IL 6,929,690$8,038,0000.50%
NEA Management Company, LLC 7,140,450$8,283,0000.33%
Orbimed Advisors 9,520,600$11,044,0000.16%
Renaissance Technologies 2,103,792$2,440,0000.00%
Paloma Partners Management Co 30,289$35,0000.00%
WEDBUSH SECURITIES INC 12,600$15,0000.00%
HRT FINANCIAL LP 19,710$22,0000.00%
FIRST MANHATTAN CO. LLC. 33$00.00%
View complete list of CTI BIOPHARMA CORP shareholders